In Chinese adults with type 2 diabetes, semaglutide 1 mg once weekly changed HbA1c from baseline by -1.43% at week 12 (placebo 0.28%), in a trial where it was the active control.
In plain wordsIn Chinese adults with type 2 diabetes, semaglutide 1 mg lowered HbA1c by 1.43% over 12 weeks, while HbA1c rose 0.28% on placebo.
- Peptide
- Semaglutide
- Outcome
- DecreaseHbA1c change from baseline at week 12
- Study
n = 16
- Analysis
- Primary
- Outcome group
- Glycemic control · Metabolic and weight
- Studied dose
- 1 mg · subcutaneous · 12 weeksAs given in this study (human).
Measurements
- HbA1c change
- −1.43%
- semaglutide 1 mg, week 12
- HbA1c change
- 0.28%
- placebo, week 12
Source sentences
At Week 12, the mean changes in HbA1c from baseline were -1.72% for the 5 mg dose, -1.94% for the 10 mg dose, -2.48% for the 15 mg dose, -1.43% for 1 mg semaglutide and 0.28% for placebo, with the treatment differences versus placebo (LSM) ranging from -1.82% to -2.56% (all p < 0.05).
3 context sentences(design, population, supporting numbers)
The primary endpoint was the change in HbA1c from baseline, and secondary endpoints included fasting plasma glucose (FPG), 2-h plasma glucose (2 h PG) and body weight.
In this multicentre, randomised, placebo-controlled and semaglutide-positive-controlled trial, 64 Chinese adults with T2DM were randomly assigned to BGM0504 5 mg (n = 12), 10 mg (n = 12), 15 mg (n = 12), placebo (n = 12) or semaglutide 1 mg (n = 16).
All participants received their assigned dose once weekly for 12 weeks.